Quantcast

Latest Areva Med Stories

2014-07-07 08:22:53

DALLAS, July 7, 2014 /PRNewswire/ -- Macrocyclics, Inc. (an AREVA Med company) announced today the launch of new offices located in China, Japan, South Korea, and France. The production laboratory remains based in Dallas, Texas, USA; however, Asian and French customers will now have a local contact for placing orders and obtaining technical information about all products and services available from Macrocyclics, and the ability to communicate in their own language as well as...

2014-01-10 12:25:57

DALLAS, Jan. 10, 2014 /PRNewswire/ -- Macrocyclics, Inc. (an AREVA Med company) announced today the introduction of four new products that will expand PET imaging applications with copper-64 and gallium-68 using NOTA-based chelating platforms. In addition, a new serotonin-based DOTA conjugate offers the potential to image serotoninergic neurotransmission using a radioisotope or with gadolinium by magnetic resonance imaging (MRI). (Logo:...

2011-08-05 00:00:29

AREVA announced that its subsidiary AREVA Med has started a Phase 1 clinical trial for its lead product ²¹²Pb-TCMC-Trastuzumab in patients with HER-2 positive intra-abdominal cancers. Bethesda, MD (PRWEB) August 04, 2011 AREVA announced that its subsidiary AREVA Med has started a Phase 1 clinical trial for its lead product ²¹²Pb-TCMC-Trastuzumab in patients with HER-2 positive intra-abdominal cancers. The new trial (AREVAMED01) is an open label Phase 1, dose...

2011-01-25 00:02:22

AREVA announced today that its subsidiary AREVA Med, which specializes in nuclear medicine, has received authorization from the Food and Drug Administration (FDA) to begin U.S. clinical trials for a new treatment aimed at combating cancer. Bethesda, Md. (Vocus/PRWEB) January 24, 2011 AREVA announced today that its subsidiary AREVA Med, which specializes in nuclear medicine, has received authorization from the Food and Drug Administration (FDA) to begin U.S. clinical trials for a new...

2010-04-19 08:17:01

The American Cancer Society estimates one man in six will get prostate cancer during his lifetime, making it the second-leading cause of cancer death in men. With a new partnership with Areva Med, UC researchers will investigate the use of a new drug in stopping the growth of prostate cancer tumors. In the study, UC researchers in the lab of Zhongyun Dong, PhD, will test the efficacy of a new agent targeted against a specific protein on the surface of the tumor. "It's been shown that human...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.